Related Experiment Video

Updated: Aug 14, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Increased D-glucaric acid excretion in children with renal disease

I Németh, T Szeleczki

    International Journal of Clinical Pharmacology, Therapy, and Toxicology
    |January 1, 1980
    PubMed

    Insights

    Urinary D-glucaric acid excretion, a marker for microsomal enzyme activity, significantly increases in infants and children with early-stage renal disease, particularly tubulopathy and pyelonephritis.

    Area of Science:

    • Biochemistry
    • Pediatric Nephrology
    • Pharmacology

    Background:

    • Microsomal enzyme activity is crucial for drug metabolism.
    • Assessing enzyme activity in pediatric renal disease is clinically important.
    • Urinary D-glucaric acid is a known biomarker for enzyme induction.

    Purpose of the Study:

    • To assess non-specific microsomal enzyme activity in infants and children with renal disease.
    • To investigate the correlation between renal disease severity and D-glucaric acid excretion.
    • To explore the implications of altered enzyme activity in pediatric nephropathies.

    Main Methods:

    • Measured urinary D-glucaric acid excretion in 85 infants and children.
    • Compared excretion levels between patients with various renal diseases and healthy controls.
    • Analyzed data considering the influence of enzyme-inducing drugs.

    Main Results:

    • Significantly elevated urinary D-glucaric acid excretion was observed in early stages of renal disease.
    • The increase was most pronounced in patients with tubulopathy and pyelonephritis.
    • Elevated excretion was noted even in patients receiving enzyme-inducing drugs, suggesting disease-specific alterations.

    Conclusions:

    • Early-stage renal disease in children is associated with increased microsomal enzyme activity.
    • Urinary D-glucaric acid is a sensitive indicator of renal disease in pediatric populations.
    • Findings suggest potential therapeutic strategies targeting drug metabolism in pediatric renal patients.

    More Related Videos

    Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells09:40

    Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

    Published on: June 20, 2018

    Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro14:18

    Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

    Published on: October 13, 2023

    Related Concept Videos

    Glucose Transporters01:27

    Glucose Transporters

    Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
    Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

    Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

    In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance (Clcr), a...
    Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

    Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

    Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
    Diabetic Ketoacidosis l: Introduction01:25

    Diabetic Ketoacidosis l: Introduction

    DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...